PDCD1 and colorectal carcinoma: In addition to positive results from the KEYNOTE-177 trial, a phase II trial involving neoadjuvant treatment of MSI-H CRC patients with the anti-PD-1 mAb toripalimab caused a high pathological complete response rate and an acceptable safety profile [61].